Veeral Sheth to Receptors, Vascular Endothelial Growth Factor
This is a "connection" page, showing publications Veeral Sheth has written about Receptors, Vascular Endothelial Growth Factor.
Connection Strength
0.496
-
Comparison of the efficacy and safety of SCD411 and reference aflibercept in patients with neovascular age-related macular degeneration. Sci Rep. 2024 06 26; 14(1):14752.
Score: 0.213
-
ACTINOMYCES NEUII ENDOPHTHALMITIS AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTION. Retin Cases Brief Rep. 2017 Summer; 11(3):281-282.
Score: 0.132
-
Anti-VEGF Pharmaceutical Prior Authorization in Retina Practices. JAMA Ophthalmol. 2024 Aug 01; 142(8):716-721.
Score: 0.054
-
Efficacy and Safety of Brolucizumab for Diabetic Macular Edema: The KINGFISHER Randomized Clinical Trial. JAMA Ophthalmol. 2023 12 01; 141(12):1152-1160.
Score: 0.051
-
A Randomized, Double-Masked, Multicenter Trial of Topical Acrizanib (LHA510), a Tyrosine Kinase VEGF-Receptor Inhibitor, in Treatment-Experienced Subjects With Neovascular Age-Related Macular Degeneration. Am J Ophthalmol. 2022 07; 239:180-189.
Score: 0.045